Cybin Inc
Research Cybin Inc (HELP) on Bullrun: market cap USD 731.41M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerHELP
- ExchangeNYSE MKT
- CountryCanada
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 731.41M
- Financial periodFY2026
- RevenueUSD 0
- Net income-USD 148.00M
- Free cash flow-USD 134.64M
Valuation Snapshot
latest market cap is USD 731.41M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2026 | USD 0 | -USD 148.00M | -USD 134.64M | n/a | -4.25 | USD 157.26M | n/a | USD 231.79M |
| FY2025 | USD 0 | -USD 81.61M | -USD 73.72M | n/a | -4.04 | USD 93.92M | USD 0 | USD 165.00M |
| FY2024 | USD 0 | -USD 54.37M | -USD 48.47M | n/a | -4.85 | USD 145.52M | USD 202.62K | USD 203.26M |
| FY2023 | USD 0 | -USD 47.49M | -USD 50.74M | n/a | -9.88 | USD 16.63M | n/a | USD 48.23M |
| FY2022 | USD 0 | -USD 67.63M | -USD 45.73M | n/a | -15.2 | USD 53.64M | n/a | USD 76.16M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 731.41M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 408.13M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 176.41M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 166.64M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 52.46M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 651.26M | n/a | n/a | n/a |
About Cybin Inc
Helus Pharma Inc., doing business as Helus Pharma, operates as a clinical stage pharmaceutical company that focuses on developing therapies to treat psychiatric and neurological conditions. It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder; and HLP004, a deuterated N, N-dimethyltryptamine, which is in phase 2 clinical trial for treating generalized anxiety disorders.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Cybin Inc's market cap?
Cybin Inc's market capitalization is USD 731.41M.
What does Cybin Inc do?
Helus Pharma Inc., doing business as Helus Pharma, operates as a clinical stage pharmaceutical company that focuses on developing therapies to treat psychiatric and neurological conditions. It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder; and HLP004, a deuterated N, N-dimethyltryptamine, which is in phase 2 clinical trial for treating generalized anxiety disorders. The company's preclinical product includes HLP005, a phenethylamine and tryptamine derivative to treat central nervous system.